Published in Ann Oncol on January 14, 2005
Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. Trends Mol Med (2007) 1.08
Chemotherapy advances in small-cell lung cancer. J Thorac Dis (2013) 1.08
Treatment options for small cell lung cancer - do we have more choice? Br J Cancer (2010) 1.07
Small cell lung cancer: therapies and targets. Semin Oncol (2013) 1.02
Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer. Int J Clin Oncol (2009) 0.85
Amrubicin for non-small-cell lung cancer and small-cell lung cancer. Invest New Drugs (2007) 0.85
Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin. Drug Des Devel Ther (2009) 0.83
C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin. Clin Med Insights Oncol (2013) 0.83
Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs (2007) 0.82
Advanced small cell carcinoma of the uterine cervix treated by neoadjuvant chemotherapy with irinotecan and cisplatin followed by radical surgery. Rare Tumors (2011) 0.81
Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride. Clin Med Insights Oncol (2011) 0.78
Effective monotherapy with amrubicin for a refractory extrapulmonary small-cell carcinoma of the liver. Case Rep Med (2009) 0.78
Ovarian small cell carcinoma complicated by carcinomatous meningitis. Rare Tumors (2012) 0.76
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer (2016) 0.75
Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer. Cancer Sci (2016) 0.75
Chemotherapy for small cell lung cancer: a comprehensive review. Oncol Rev (2012) 0.75
Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer. Drug Des Devel Ther (2013) 0.75
VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell (1990) 8.87
Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 6.36
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature (2000) 6.01
Nrl is required for rod photoreceptor development. Nat Genet (2001) 5.68
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol (1999) 5.65
Tumor induction of VEGF promoter activity in stromal cells. Cell (1998) 5.20
Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. J Biol Chem (1988) 5.18
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia (1996) 5.06
Repression domains of class II ERF transcriptional repressors share an essential motif for active repression. Plant Cell (2001) 4.19
The dinB gene encodes a novel E. coli DNA polymerase, DNA pol IV, involved in mutagenesis. Mol Cell (1999) 4.01
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med (2001) 3.69
Multiple pathways for SOS-induced mutagenesis in Escherichia coli: an overexpression of dinB/dinP results in strongly enhancing mutagenesis in the absence of any exogenous treatment to damage DNA. Proc Natl Acad Sci U S A (1997) 3.53
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood (1999) 3.46
Autophagosome requires specific early Sec proteins for its formation and NSF/SNARE for vacuolar fusion. Mol Biol Cell (2001) 3.41
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res (1998) 3.20
Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest (2000) 2.96
Characterization of the cell surface heterodimer VLA-4 and related peptides. J Biol Chem (1987) 2.94
Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain. J Biol Chem (1996) 2.72
Amino-terminal presequence of the precursor of peroxisomal 3-ketoacyl-CoA thiolase is a cleavable signal peptide for peroxisomal targeting. Biochem Biophys Res Commun (1991) 2.71
Molecular basis for resistance to silver cations in Salmonella. Nat Med (1999) 2.62
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol (1992) 2.58
Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol (1997) 2.55
Fibronectin receptor structures in the VLA family of heterodimers. Nature (1987) 2.54
Flow-cytometric separation and enrichment of hepatic progenitor cells in the developing mouse liver. Hepatology (2000) 2.43
The 70-kDa peroxisomal membrane protein is a member of the Mdr (P-glycoprotein)-related ATP-binding protein superfamily. J Biol Chem (1990) 2.40
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol (2012) 2.38
Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol (1996) 2.38
Uveal effusion syndrome: clinical features, surgical treatment, histologic examination of the sclera, and pathophysiology. Ophthalmology (2000) 2.36
Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia (1998) 2.35
NK1.1+ CD4+ CD8- thymocytes with specific lymphokine secretion. Eur J Immunol (1993) 2.32
Intact motility as a Salmonella typhi invasion-related factor. Infect Immun (1988) 2.32
Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation (1996) 2.31
Roles of chromosomal and episomal dinB genes encoding DNA pol IV in targeted and untargeted mutagenesis in Escherichia coli. Mol Genet Genomics (2001) 2.31
Evolutionary adaptation of plasmid-encoded enzymes for degrading nylon oligomers. Nature (1984) 2.29
Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun (1986) 2.27
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer (2008) 2.21
Multiple very late antigen (VLA) heterodimers on platelets. Evidence for distinct VLA-2, VLA-5 (fibronectin receptor), and VLA-6 structures. J Biol Chem (1988) 2.20
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer (2008) 2.19
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol (2009) 2.14
Follow-up study after intracranial percutaneous transluminal cerebral balloon angioplasty. AJNR Am J Neuroradiol (1998) 2.12
The very late antigen family of heterodimers is part of a superfamily of molecules involved in adhesion and embryogenesis. Proc Natl Acad Sci U S A (1987) 2.11
Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol (2001) 2.10
Patients' understanding and opinion about informed consent for coronary angiography in a rural Japanese hospital. Intern Med (1998) 2.10
Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest (1999) 2.09
Distinct functions of integrin alpha and beta subunit cytoplasmic domains in cell spreading and formation of focal adhesions. J Cell Biol (1993) 2.08
Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis (2000) 2.07
Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol (2000) 2.07
Accumulation of GTP-bound RhoA during cytokinesis and a critical role of ECT2 in this accumulation. J Biol Chem (2000) 2.04
A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group. J Clin Oncol (1993) 2.02
A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med (1980) 2.01
Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem (1991) 2.01
Structure of a beta-galactosidase gene of Bacillus stearothermophilus. J Bacteriol (1986) 1.99
Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody. J Immunol (1988) 1.96
Characterization of a novel acidic protein of 38 kDa, A0, in yeast ribosomes which immunologically cross-reacts with the 13 kDa acidic ribosomal proteins, A1/A2. J Biochem (1987) 1.93
Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res (2001) 1.91
6-Aminohexanoic acid cyclic dimer hydrolase. A new cyclic amide hydrolase produced by Achromobacter guttatus KI74. Eur J Biochem (1977) 1.91
Retrospective analysis of 1502 patients with facial fractures. Int J Oral Maxillofac Surg (2001) 1.91
Video-assisted thoracoscopic surgery for small indeterminate pulmonary nodules: indications for preoperative marking. Chest (1999) 1.90
Demonstration of mother-to-infant transmission of hepatitis B virus by means of polymerase chain reaction. Lancet (1989) 1.90
Treatment of gallbladder cancer by radical resection. Br J Surg (1999) 1.88
An experimental study of a combination method using a pedicle screw and laminar hook for the osteoporotic spine. Spine (Phila Pa 1976) (1997) 1.88
Ehrlichia muris sp. nov., identified on the basis of 16S rRNA base sequences and serological, morphological, and biological characteristics. Int J Syst Bacteriol (1995) 1.86
IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol (1996) 1.85
Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the rat. Kidney Int (1998) 1.85
In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells. Science (1991) 1.85
Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions. Immunol Rev (1990) 1.83
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer (2001) 1.81
Western immunoblot analysis of Haemobartonella muris and comparison of 16S rRNA gene sequences of H. muris, H. felis, and Eperythrozoon suis. J Clin Microbiol (1997) 1.80
Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1. J Cell Biol (1990) 1.78
Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther (2001) 1.77
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol (2009) 1.76
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol (2003) 1.75
Exercise-induced U-wave alterations as a marker of well-developed and well-functioning collateral vessels in patients with effort angina. J Am Coll Cardiol (2000) 1.73
Integrins alpha2beta1 and alpha4beta1 can mediate SA11 rotavirus attachment and entry into cells. J Virol (2000) 1.72
p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res (1992) 1.72
Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int (2000) 1.72
Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers. Am J Surg Pathol (1980) 1.72
Purification and initial characterization of a protein which facilitates assembly of nucleosome-like structure from mammalian cells. Eur J Biochem (1984) 1.71
Isolation and characterization of Chinese hamster ovary cell mutants defective in assembly of peroxisomes. J Cell Biol (1990) 1.71